Spyre Therapeutics prices follow-on stock offering at USD 350 million
Bitget2026/10/06 00:14Spyre Therapeutics priced an underwritten public offering of 4,117,648 common shares at USD 85.00 each. Gross proceeds expected at about USD 350 million; underwriters hold a 30-day option for up to about USD 52.5 million more. Closing targeted for Oct. 7, 2026, subject to customary conditions. Net proceeds earmarked to advance immunology pipeline programs, including late-stage development plans for SPY072 in hidradenitis suppurativa. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610052013PRIMZONEFULLFEED9840149) on October 06, 2026, and is solely responsible for the information contained therein.
- Spyre Therapeutics priced an underwritten public offering of 4,117,648 common shares at USD 85.00 each.
- Gross proceeds expected at about USD 350 million; underwriters hold a 30-day option for up to about USD 52.5 million more.
- Closing targeted for Oct. 7, 2026, subject to customary conditions.
- Net proceeds earmarked to advance immunology pipeline programs, including late-stage development plans for SPY072 in hidradenitis suppurativa.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October


SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

Quantumrail Cancels 10 Billion Won Convertible Bond Offering